Tianjin Ascent Technology

Ascentage Pharma is a global biopharmaceutical company focused on developing novel therapies for cancers, hepatitis B virus (HBV), and age-related diseases by targeting protein-protein interactions to restore apoptosis. The company's lead product, olverembatinib (HQP1351), is a third-generation BCR-ABL inhibitor approved in China for the treatment of patients with T315I-mutant chronic myeloid leukemia. Ascentage boasts a robust pipeline of small molecule candidates, including lisaftoclax (APG-2575), a BCL-2 inhibitor currently in global registrational trials. With a strong R&D foundation in Tianjin and Suzhou, the company is the first to have clinical-stage assets targeting the BCL-2, IAP, and MDM2-p53 pathways simultaneously. Ascentage is listed on the Hong Kong Stock Exchange and maintains strategic partnerships with global leaders like Takeda and AstraZeneca.